Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DE:DYF1)
FRANKFURT:DYF1
Holding DE:DYF1?
Track your performance easily
DYF1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€8.60 - €13.69
Previous Close€10.16
Volume0.00
Average Volume (3M)126.00
Market Cap
€1.32B
Enterprise Value€874.21M
Total Cash (Recent Filing)$735.61M
Total Debt (Recent Filing)$250.75M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Oct 31, 2024EPS Estimate
€0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding131,044,383
10 Day Avg. Volume16
30 Day Avg. Volume126
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.01
Price to Sales (P/S)5.78
Price to Cash Flow (P/CF)33.70
P/FCF Ratio32.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.50
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda44.58
Forecast
1Y Price Target
€22.31Price Target Upside119.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Dynavax News
PremiumCompany Announcements
Kelly MacDonald Returns as CFO to Dynavax Technologies
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDynavax reaffirmed FY24 Heplisav-B net product revenue guidance of between $265M-$280M.
Future Market OpportunityManagement reiterated its expectation for a HepB market opportunity of >$800M in 2027, with HEPLISAV-B having a majority share.
Market Share GrowthHEPLISAV-B is likely to continue to take market share due to its advantageous profile in a market growing on increased awareness.
Bears Say
Pipeline DevelopmentAbsence of near-term derisking catalysts for the company's early-stage pipeline, which is likely to remain in a holding pattern for the foreseeable future.
Regulatory ChallengesThe FDA issued a Complete Response Letter for Heplisav's sBLA in adults on hemodialysis citing insufficient data due to the destruction of records by a trial site.
Sales PerformanceDVAX reported its 2Q24 results with sales of its Heplisav-B vaccine coming in below Visible Alpha Consensus Data.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.37% Insiders
23.98% Mutual Funds
0.03% Other Institutional Investors
51.23% Public Companies and
Individual Investors
DYF1 FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was €8.60 and its highest was €13.69 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Currently, no data Available
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Oct 31, 2024 which is in 23 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Aug 06, 2024. The company reported €0.073 earnings per share for the quarter, beating the consensus estimate of €0.059 by €0.014.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is €0.11.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 131,044,390 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of €0.073 in its last earnings report, beating expectations of €0.059. Following the earnings report the stock price went up 1.86%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Among the largest hedge funds holding Dynavax Technologies Corp.’s share is Fisher Asset Management LLC. It holds Dynavax Technologies Corp.’s shares valued at 16M.
---
Dynavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.31 (119.66% Upside)
€22.31 (119.66% Upside)
Blogger Sentiment
Bullish
DE:DYF1 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.15%
12-Months-Change
Fundamentals
Return on Equity
2.82%
Trailing 12-Months
Asset Growth
8.53%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DYF1 Company Deck
---
DYF1 Earnings Call
Q2 2024
0:00 / 0:00
---
DYF1 Stock 12 Month Forecast
Average Price Target
€22.31
▲(119.66% Upside)
Technical Analysis
Best Analysts Covering DYF1
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
-0.02%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of -0.02% per trade.
---